A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
Alkem Medtech to acquire 100% stake of Bombay Ortho
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The facility will have a capacity to manufacture upto 3 million tubes monthly
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
This registration enables companies to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Subscribe To Our Newsletter & Stay Updated
